Literature DB >> 28954837

Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature.

Manuel Schiff1,2, Céline Roda3, Marie-Lorraine Monin4, Alina Arion5, Magali Barth6,7, Nathalie Bednarek8, Maud Bidet9, Catherine Bloch10, Nathalie Boddaert11,12,13, Delphine Borgel6,7, Anaïs Brassier3, Alexis Brice14,15,16,17, Arnaud Bruneel18, Roger Buissonnière19, Brigitte Chabrol20, Marie-Chantal Chevalier21, Valérie Cormier-Daire22,23,24, Claire De Barace25, Emmanuel De Maistre26, Anne De Saint-Martin27, Nathalie Dorison28, Valérie Drouin-Garraud29, Thierry Dupré, Bernard Echenne30, Patrick Edery31, François Feillet32, Isabelle Fontan33, Christine Francannet34, François Labarthe35, Cyril Gitiaux36, Delphine Héron37, Marie Hully3, Sylvie Lamoureux38, Dominique Martin-Coignard39, Cyril Mignot4, Gilles Morin40, Tiffany Pascreau6,7, Olivier Pincemaille41, Michel Polak9, Agathe Roubertie, Christel Thauvin-Robinet42, Annick Toutain43, Géraldine Viot44, Sandrine Vuillaumier-Barrot18, Nathalie Seta18, Pascale De Lonlay3.   

Abstract

BACKGROUND: Phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG) is a multisystem inborn error of metabolism.
OBJECTIVES: To better characterise the natural history of PMM2-CDG.
METHODS: Medical charts of 96 patients with PMM2-CDG (86 families, 41 males, 55 females) were retrospectively reviewed. Data on clinical, laboratory and molecular parameters at diagnosis were analysed. Follow-up data at last examination were reported for 25 patients.
RESULTS: The patients were born between 1963 and 2011. Diagnosis of PMM2-CDG was made at a mean (SD) age of 6.8 (8.5) years. The presenting signs were mostly neurological (hypotonia, intellectual disability, cerebellar syndrome) and observed in almost all the patients. A total of 38 patients (14 males, 24 females) exhibited, in addition to neurological signs, visceral features including at least one of these: feeding difficulty requiring a nutritional support (n=23), cardiac features (n=20; pericarditis: 14, cardiac malformation: 9, cardiomyopathy: 2), hepato-gastrointestinal features (n=12; chronic diarrhoea: 7, protein-losing enteropathy: 1, ascites: 3, liver failure: 1, portal hypertension: 1), kidney features (n=4; nephrotic syndrome: 2, tubulopathy: 2) and hydrops fetalis (n=1). Twelve patients died at a mean age of 3.8 years (especially from pericarditis and other cardiac issues). Laboratory abnormalities mostly included elevated transaminases and abnormal coagulation parameters. High thyreostimulin levels, hypocholesterolemia, hypoalbuminemia and elevated transaminases were associated with the visceral phenotype. Besides the common Arg141His PMM2 variant harboured by half of the patients, 45 different variants were observed.
CONCLUSIONS: PMM2-CDG clinical phenotype is heterogeneous in terms of clinical course, with no clear division between neurological and visceral presentations. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  CDG-I; PMM2-CDG; congenital disorders of glycosylation; phosphomannomutase

Mesh:

Substances:

Year:  2017        PMID: 28954837     DOI: 10.1136/jmedgenet-2017-104903

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  22 in total

Review 1.  Recognizable phenotypes in CDG.

Authors:  Carlos R Ferreira; Ruqaia Altassan; Dorinda Marques-Da-Silva; Rita Francisco; Jaak Jaeken; Eva Morava
Journal:  J Inherit Metab Dis       Date:  2018-04-13       Impact factor: 4.982

Review 2.  Congenital disorders of glycosylation.

Authors:  Irene J Chang; Miao He; Christina T Lam
Journal:  Ann Transl Med       Date:  2018-12

Review 3.  Nutrition interventions in congenital disorders of glycosylation.

Authors:  Suzanne W Boyer; Christin Johnsen; Eva Morava
Journal:  Trends Mol Med       Date:  2022-05-10       Impact factor: 15.272

4.  Neurological Consequences of Congenital Disorders of Glycosylation.

Authors:  Justyna Paprocka
Journal:  Adv Neurobiol       Date:  2023

5.  Cystic kidney diseases associated with mutations in phosphomannomutase 2 promotor: a large spectrum of phenotypes.

Authors:  Guillaume Dorval; Cécile Jeanpierre; Vincent Morinière; Carole Tournant; Bettina Bessières; Tania Attié-Bittach; Jeanne Amiel; Emmanuel Spaggari; Yves Ville; Elodie Merieau; Marie-Claire Gubler; Sophie Saunier; Laurence Heidet
Journal:  Pediatr Nephrol       Date:  2021-02-13       Impact factor: 3.714

6.  High N-glycan multiplicity is critical for neuronal adhesion and sensitizes the developing cerebellum to N-glycosylation defect.

Authors:  Daniel Medina-Cano; Ekin Ucuncu; Lam Son Nguyen; Michael Nicouleau; Joanna Lipecka; Jean-Charles Bizot; Christian Thiel; François Foulquier; Nathalie Lefort; Catherine Faivre-Sarrailh; Laurence Colleaux; Ida Chiara Guerrera; Vincent Cantagrel
Journal:  Elife       Date:  2018-10-12       Impact factor: 8.140

7.  Liver Involvement in Congenital Disorders of Glycosylation and Deglycosylation.

Authors:  Patryk Lipiński; Anna Bogdańska; Piotr Socha; Anna Tylki-Szymańska
Journal:  Front Pediatr       Date:  2021-07-05       Impact factor: 3.418

8.  Liver Involvement in Congenital Disorders of Glycosylation: A Systematic Review.

Authors:  Rossella Colantuono; Elisa D'Acunto; Daniela Melis; Pietro Vajro; Hudson H Freeze; Claudia Mandato
Journal:  J Pediatr Gastroenterol Nutr       Date:  2021-10-01       Impact factor: 3.288

Review 9.  Nutritional Therapies in Congenital Disorders of Glycosylation (CDG).

Authors:  Peter Witters; David Cassiman; Eva Morava
Journal:  Nutrients       Date:  2017-11-07       Impact factor: 5.717

10.  Impact of novel oncogenic pathways regulated by antitumor miR-451a in renal cell carcinoma.

Authors:  Yasutaka Yamada; Takayuki Arai; Sho Sugawara; Atsushi Okato; Mayuko Kato; Satoko Kojima; Kazuto Yamazaki; Yukio Naya; Tomohiko Ichikawa; Naohiko Seki
Journal:  Cancer Sci       Date:  2018-03-09       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.